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ABSTRACT: 
Mucoadhesion is defined as the adherence of a synthetic or natural polymer to a mucosal 
membrane via physical or chemical interactions.  Mucoadhesive materials are widely used to 
develop dosage forms for transmucosal drug delivery via ocular, nasal, esophageal, oral, 
vaginal, rectal and intravesical routes of administration. This review will discuss some of the 
most prominent and recent synthetic methodologies employed to modify polymeric materials 
in order to enhance their mucoadhesive properties. This includes chemical conjugation of 
polymers with molecules bearing thiol-, catechol-, boronate-, acrylate-, methacrylate-, 




Introduction to mucosae and mucoadhesion 
Mucosae and mucin 
Mucosae or mucous membranes are defined as moist tissue linings which envelop all cavities 
and canals which communicate with the exterior i.e. the eyes, gastrointestinal tract, 
genitourinary tract, respiratory passages consisting of a mucus covered outer epithelial layer 
and a sub-layer of connective tissue (lamina propria) which form a protective barrier for 
underlying structures.[1] The surface epithelial stratum can present itself as either a single 
layered (bronchi, stomach and intestine) or multi-layered (cornea, oesophagus, vagina) 
structure which, in the latter instance, contains or are neighboured by dedicated glands which 
secrete mucus onto the epithelia i.e. submucosal esophageal glands/esophageal cardiac glands 
present in the oesophagus. Additionally, cavities or canals consisting of single layered epithelia 
containing modified columnar epithelial cells, known as goblet cells, which secrete mucus 
directly onto the outer epithelial layer (Figure 1).[1-3]  
 
Figure 1. Schematic of mucosal membrane 
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Secreted mucus layers are adherent viscous colloidal gels comprising predominantly of 
extracellular glycoproteins, lipids such as fatty acids, phospholipids, inorganic salts, 
cholesterol, defensive proteins (i.e. lysosomes, defensins, trefoil factors etc.) and water 
(~95%), in which mucin glycoproteins provide the main structure-forming characteristics of 
the gel.[4] Mucins are large extracellular glycoproteins (0.5-20 MDa), characteristically 
consisting of a linear protein ‘core’, which is ~20% of the total molecular mass (200-500 kDa) 
and a partially branched carbohydrate proponent which makes up the remaining ~80% of the 
total composition of the mucin glycoprotein.[4-6] These glycoproteins are negatively charged 
due to the presence of terminal sialic acid (pKa of 2.6) and sulphate groups.[7]   
 
Figure 2. Basic schematic drawing of mucin glycoprotein 
The protein core may be broken down into two component regions; the cysteine rich (>10%) 
N- and C- termini ‘globular protein-like’ regions, involved in the dimerization of mucins 
through disulphide bond formations, and a highly glycosylated ‘bottle-brush’ central region 
consisting of tandemly repeated amino acids abundant in O-glycosylated threonine and serine 
residues (Figure 2).[8] The polysaccharide ‘brushes’ of the mucins are made up of carbohydrate 























acetylgalactosamine, N-acetylglucosamine, fucose, galactose, N-acetylneuraminic acid and 
traces of mannose. The intermolecular interpenetration of these polysaccharide brushes, in 
combination with non-transient interactions of the cysteine-rich regions, is essential for the 
maintenance of the gel matrix.[8, 9]  
When speaking in terms of biomaterials science, mucoadhesion is defined as the adherence of 
a synthetic or natural polymer to a mucosal membrane via physical or chemical interactions.[10] 
Mucoadhesive materials are widely used to develop dosage forms for transmucosal drug 
delivery via ocular, nasal, esophageal, oral, vaginal, rectal and intravesical routes of 
administration.[11-16] The advantages offered by mucoadhesive formulations include the ease of 
dosage form administration, possibility of therapy termination (e.g. mucoadhesive tablets in 
the mouth), improved drug bioavailability, possibility of targeting particular organs (e.g. nasal 
route of administration provides access to central nervous system), etc. In addition to drug 
delivery, mucoadhesive materials are finding applications in food industry.[17, 18] Many theories 
pertaining to the predominant mechanisms of mucoadhesion have been proposed (Table 1). 
The mechanisms of adhesion to mucosa could be different and dependent on the nature of a 
dosage form. For example, solid dosage forms (such as tablets) will be affected by the process 
of hydration, whereas adhesion of liquid formulations will be more influenced by their 
rheological properties. The main focus of this manuscript will be the interactions best described 
by adsorption theory, specifically mucoadhesion occurring as a consequence of ‘primary 
bonding’ (i.e. covalent and ionic bonds).[10] Furthermore this review will highlight some of the 
most prominent synthetic methodologies employed to modify polymeric materials in order to 






Table 1. Theories of mucoadhesion[10, 11, 19] 
Theory of 
mucoadhesion 
Applicability of the theory and main mechanisms involved 
Electronic 
This theory considers a transfer of electrons between the dosage form and 
mucosal surface, which leads to formation of electrical double layer at 
the interface, resulting in electrostatic attraction. 
Absorption 
This theory relates mucoadhesion to formation of either weak physical 
bonds (hydrogen bonding, van der Waals forces) or/and strong covalent 
bonds between the material of a dosage form and mucins. 
Wetting 
Mostly applicable to liquid dosage forms. The theory considers the ability 
of a dosage form to spread on mucosal surface, which is associated with 
stronger mucoadhesive properties 
Diffusion 
This theory looks at penetration of macromolecules present in a dosage 
form into the mucus gel and formation of an interpenetrating layer. This 
penetration will be affected by the molecular weight of mucoadhesive 
and flexibility of macromolecules. 
Fracture 
This theory relates the forces required for the separation of a dosage form 
from mucosa after adhesion bond is formed 
Mechanical 
Adhesion results from interlocking of a liquid dosage form into 
irregularities on a rough mucosal surface 
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First generation (non-specific) primary bonding mucoadhesive materials  
Cationic materials 
As a consequence of the anionic nature of mucin glycoproteins, the exploitation of potential 
electrostatic interactions with cationic materials was cited as one of the earliest primary 
bonding methods employed in designing new mucoadhesive systems.[20] Owing to its 
biodegradability, biocompatibility and inherent cationic nature, chitosan, a semi-synthetic 
polyaminosaccharide, has been the most highly exploited of the first generation mucoadhesive 
materials.[21-23] 
 
Figure 3. Deacetylation of chitin to yield chitosan. 
Widely commercially available, chitosan is obtained through the deacetylation of the naturally 
occurring chitin, yielding, at varying degrees, free amine groups along the polysaccharide 
backbone (Figure 3). Owing to the pKa of these free amine groups (~ 6.3), chitosan is only 
soluble in acidic solutions (pH <6.0) when the amines become protonated, producing a cationic 
polyelectrolyte. This, in combination with hydrophobic and H-bonding interactions, allows for 
chitosan to effectively and non-specifically bind to the mucosal surface.[24] In order to assess 
its viability as a potential pharmaceutical excipient, chitosan has been formulated into 
nanoparticles, microspheres, liposomes, capsules, fibres, beads, films, freeze-dried wafers, gels 
and tablets.[25-32] Furthermore, chitosan has been modified with a plethora of mucoadhesivity- 
enhancing moieties[33], some of which will be discussed later. Recently, some attempts were 






established that novel aminated cellulose derivative exhibits better mucoadhesive performance 
than chitosan. Similarly, poly(L-lysine) (PLL), is a naturally derived polyamine containing 
synthetic peptide, which also exhibits good mucoadhesive properties owing to its cationic 
nature.[20, 35-37] However PLL has been utilised far less than chitosan in pharmaceutical sciences 
owing to processing/formulation difficulties and relatively poor commercial availability.  In 
addition to natural amino bearing polymers, synthetic non-degradable polymers 
poly(allylamine) hydrochloride (PAH) and poly((2-dimethylamino)ethyl methacrylate) 
(PDMAEMA) have also been investigated for their mucoadhesive capabilities. Both PAH and 
PDMAEMA are synthesised via radical polymerisation techniques (e.g. vinyl addition, free 
radical or controlled radical polymerisation), employing the commercially available allyl 
amine and 2-(dimethylamino)ethyl methacrylate monomers, respectively. Akin to chitosan, 
these synthetic materials were found to exhibit enhanced mucoadhesive properties in acidic 
environments owing to protonation of the amine derivatives.[38, 39] Furthermore these materials 
can be easily formulated into nanogels, liposomes and films, however, in the case of PAH, 
toxicity issues have restricted its application somewhat.[40] Some other synthetic copolymers 
based on [2-(methacryloyloxy)ethyl]trimethylammonium chloride were also reported to 




Figure 4. Examples of common first generation mucoadhesive materials. Cationic; (a) 
Chitosan, deacetylated to varying degrees, (b) poly(allylamine) hydrochloride and (c) 
PDMAEMA. Anionic; (d) Alginate, (e) poly(acrylic acid) and (f) carboxymethyl cellulose, R 
= H or CH2COOH.  
Anionic materials 
Counterintuitively, as a consequence of their incompatible charges, anionic polymers have also 
been employed as first generation mucoadhesive excipients.[42] There are comprehensive 
debates within the literature discussing the mechanism of adherence, with a large degree of 
ambiguity around the effect of and optimal pH ranges required to allow for adhesion of anionic 
materials.[14, 43-45] Like first generation cationic materials, naturally derived anionic polymers 
such as alginate, carboxymethyl cellulose (CMC) and, to a lesser degree, pectin have been 
widely used as mucoadhesive excipients owing to their carboxylic acid side groups (Figure 
4).[46-50] However, the most dominant material in the area of anionic mucoadhesives in recent 
years has been the commercially available synthetic polymer; poly(acrylic acid) (PAA).[51] 











alginate and CMC, PAA has been formulated into gels and micro-/nano-carriers by 
complexation to bivalent cations such as calcium (II), however, the most studied PAA-based 
crosslinked networks in pharmaceutical literature has been Carbopol®.[52-54] Carbopol® 
consists of PAA networks crosslinked with either allyl pentaerythritol or allyl sucrose, with 
varying degrees of crosslinking, molecular weights and viscosities available. These PAA-based 
materials have been used to prepare liposomes, coated particles, gels and micro- and nano-
particles through various formulation techniques, yielding materials with vastly enhanced 
mucoadhesive properties.[55-59] 
Second generation (specific) primary bonding mucoadhesive materials 
Thiolated materials 
Arguably the most prolific of the second generation mucoadhesive materials in pharmaceutical 
science to date, pioneered largely by Bernkop-Schnürch et al., are thiol bearing materials 
referred to as ‘thiomers’.[60-62] The conjugation of free thiols onto a polymer backbone allows 
for increased mucoadhesive capabilities through disulphide bond formation with cysteine 
residues present at the surface of the mucosa.[62] Formation of disulphide bonds between 
thiolated polymers and mucins was confirmed through a series of experiments involving  the 
mucolytic agent cysteine, whose addition results in reduction of mucoadhesive bonding, and 
also through polymer/mucus diffusion studies. Traditionally, thiomers are generated via the 
immobilisation of sulfhydryl-functional moieties onto previously-known first generation 
mucoadhesive excipients in order to further enhance their mucoadhesive capabilities.[63] As 
such, these first generation analogues can be broken into two subcategories; cationic and 
anionic thiomers, although their sulfhydryl immobilisation routes are almost identical. Two 
common methodologies for the conjugation of sulfhydryl containing compounds to both 
cationic and anionic excipients are (1) carbodiimide coupling between amines and carboxylic 
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acids (Figure 5(c)) and (2) periodate treatment of polysaccharides (i.e. chitosan, alginate etc.) 
followed by reductive amination of a cysteamine Schiff-base adducts (Figure 5(a)).[64-66] 
Additionally, the amine initiated ring-opening of 2-iminothiolane has been utilised to yield 
cationic thiomers (Figure 5(b)).[67, 68] Explicably, the most prevalent cationic thiomers are 
based on a chitosan backbone, however, cationic thiomers of hydroxyethylcellulose, 
poly(allylamine) and PDMAEMA derivatives have been synthesised.[69-72] Conversely, 
poly(acrylic acid) and polycarbophil dominate the anionic thiomer field, although alginate, 
CMC and hyaluronic acid-based backbones have also been explored.[73-76] 
 
Figure 5. Examples of thiomers. Cationic; (a) thiol-bearing chitosan, (b) thiol-bearing 
poly(allyl amine). Anionic; (c) thiol-bearing PAA, (d) preactivated thiol-bearing PAA. 
 
As a consequence of rapid thiol oxidation in aqueous solutions of pH ≥ 5, a second generation 
of thiomer known as ‘preactivated’ thiomers were designed in order to enhance the stability 
and mucoadhesive properties of first generation thiomers. Utilising previously known covalent 
chromatography techniques, thiomers containing pyridyl disulphide protecting groups were 
synthesised via disulphide exchange to yield preactivated thiomers which exhibit quantitative 





Cationic thiomers Anionic thiomers
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pyridyl leaving group, 2-mercapto-nicotinaminde (2-MNA), a derivative of vitamin B3, was 
employed as a protecting group, yielding non-toxic preactivated thiomers (Figure 5(d)). 
In an attempt to achieve materials with high incorporation of preactivated thiols, Bernkop-
Schnürch et al. synthesised the novel preactivated thiol-containing monomer 6-(2-
acryloylamino-ethyldisulfanyl)-nicotinic acid (ACENA)(Figure 6(a)). This was subsequently 
copolymerised with acrylic acid to yield preactivated anionic thiomers which exhibited 
excellent cell viability and mucopenetrative properties.[79] Other than ACENA, only one other 
bottom-up approach has been reported in the synthesis of novel thiomers. Cook et al. 
synthesised nanogels comprising of crosslinked poly(2-hydroxyethylmethacrylate-co-2-
(acetylthio)ethylacrylate) (P(HEMA-co-ATEA)) copolymers, which were subsequently treated 
with sodium thiomethoxide to yield thiol-bearing mucoadhesive nanogels.[80] 
 
Figure 6. Examples of monomers with protected thiol groups; (a) 6-(2-acryloylamino-
ethyldisulfanyl)-nicotinic acid (ACENA) and (b) 2-(acetylthio)ethylacrylate (ATEA). 
 
Catechol-bearing materials 
Since being first identified in the mussel adhesive proteins (MAPs) of marine mussels by Waite 
et al. in the 1980’s, catechol-bearing materials have been of increasingly high interest in the 




organic and inorganic surfaces.[81, 82] Although there have been pronounced advancements in 
the introduction of catechols (i.e. dopamine, hydrocaffeic acid, pyrocatechol etc.)(Figure 7) as 
adhesive-enhancing moieties through chemical modification of natural and synthetic polymers, 
the application of these materials as mucoadhesives has been somewhat limited to the 
enhancement of the mucoadhesive properties of chitosan/chitin (Cat-Chit). As mentioned 
previously, upon deacetylation, chitosan exhibits enhanced mucoadhesive properties owed to 
electrostatic interactions with the cationic chitosan and the negatively charged mucosa. 
Similarly, another important contributor of adhesive properties of MAPs is the presence of 
positively charged lysine and histidine residues; therefore chitosan offers a convenient cationic 
backbone analogous to the MAP amino acid composition.[81] The cationic nature of the Cat-
Chit formulations allows for transient mucoadhesion via electrostatic interactions before 
consolidation through catechol-mediated covalent bond formation. These covalent interactions 
occur as a consequence of o-quinone formation under physiological conditions through partial 
deprotonation of the catechols and subsequent reaction with amine and thiol residues present 
on the mucosal surface.[83-86] 
 
Figure 7. Examples of catechol-containing molecules used to modify polymer backbones; (a) 
pyrocatechol, (b) 3,4-dihydroxy benzaldehyde, (c) dopamine, (d) hydrocaffeic acid and (e) L-
DOPA. 
 




Figure 8. Synthetic routes to catechol-functionalised chitosan. Where EDC and NHS are N-(3-
diethylaminopropyl)-N′-ethylcarbodiimide and N-hydroxysuccinimide, respectively. 
 
Classically there are 5 synthetic routes to yield catechol functionalised chitosan, these are; (1) 
amide bond formation through carbodiimide coupling chemistries utilising carboxylic acid 
containing catechols (i.e. hydrocaffeic acid), (2) reductive amination of aldehyde containing 
catechols with sodium cyanoborohydride, (3) direct coupling utilising oxidants such as sodium 
periodate to yield catechol-amine adducts, (4) enzymatic synthesis utilising tyrosinase or 
laccase-mediated o-quinone formation and subsequent reaction with chitosan yielding Schiff 
base adducts and (5) electrochemical synthesis via o-quinone formation, through the 
application of an anodic potential, and subsequent reaction with electro-deposited chitosan 
yielding Schiff-base adducts (Figure 8).[87, 88] Of these synthetic strategies, carbodiimide-
(1) EDC/NHS, 
hydrocaffeic acid





(4) Enzyme (laccase or 
tyrosinase), pyrocatechol




mediated amide formation and reductive amination offer the highest degree of catechol 
conjugation (> 80 mol%), although the latter offered significantly faster reaction times. 
Boronate-bearing materials 
Owing to their ability to complex with 1,2-cis-diols, boronic acid derivatives, such as 
phenylboronic acid (PBA), have been cited as interesting prospective functionalities for 
enhancing mucoadhesive properties through interactions with saccharide residues present at 
the mucosa surface.[89] In order for the formation of cyclic boronic esters with 1,2-cis-diols, it 
is generally accepted that PBAs must be in their anionic form. However, as a consequence their 
weak acidic nature (pKa ~7-9), substituted PBA’s tend to only form boronic esters with 
monosaccharides under alkaline conditions uncommon to mucosa.[90, 91] An important 
exception to this is N-acetylneraminic acid (sialic acid), present in mucin glycoproteins, which 
can bind to PBAs under neutral and acidic (~pH 4) conditions, more common to physiological 
conditions of the mucosa (Figure 9).[92, 93] Owing to this unique capability, PBA containing 
polymers have also been utilised in detection of sialic acid expression in cancer metastasis, cell 
labelling and biosensor development.[94-97] 
 
Figure 9. Schematic of phenylboronic acid-containing materials covalently binding to sialic 
acid residues present in mucin glycoproteins. 
In an analogous methodology to the catechol functionalisation of chitosan, phenylboronic acid 









grafted to polymer scaffolds through reductive amination and carbodiimide mediated coupling 
chemistry with reasonably high degrees of conjugation.[92, 98] Most recently, Kolawole et al[99] 
reported the synthesis of boronated chitosan by the reaction with 4-carboxyphenylboronic acid 
mediated with N-3(dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride and N-
hydroxysuccinimide and demonstrated excellent mucoadhesive properties of these derivatives.   
However, more prevalently in recent times, PBAs with polymerisable functionalities such as 
cyclic carbonates, vinylic and acrylamide side groups, have been employed to yield materials 
with high PBA content while allowing for greater control over molecular weight, polymer 
morphology and higher architectures (Figure 10).[100-102] Arguably, of these PBA containing 
monomers, 3-(acrylamido)phenylboronic acid (AAPB) has received the greatest degree of 
attention as a consequence of its facile synthesis/commercial availability and several robust 
polymerisation routes, namely free radical polymerisation, reversible addition–fragmentation 
chain transfer (RAFT) polymerisation and atom-transfer radical polymerisation (ATRP). 
 
Figure 10. Examples of phenylboronic acid-containing monomers; (a) phenylboronic acid 






Prosperi-Porta et al. developed a series of poly(L-lactide)-b-poly(methacrylic acid-co-3-
acrylamidophenylboronic acid) micelles, via RAFT polymerisation, for application as 
mucoadhesive drug delivery vehicles to the ocular mucosa. Prosperi-Porta et al. demonstrated 
that PBA-containing micelles exhibited enhanced mucoadhesive capabilities when compared 
to chitosan and offered a viable route to improved ocular delivery of cyclosporine A. 
Furthermore, the in vitro cell viability showed no significant cytotoxicity in conjunction with 
minimal in vivo ocular irritation rat model.[103] 
Acrylated and methacrylated materials 
First proposed by Davidovich-Pinhas and Bianco-Peled, acrylated polymers were highlighted 
as a novel class of mucoadhesive materials owing to their ability to covalently bind with 
cysteine residues, present in mucin glycoproteins, via a Michael-type addition reaction.[104] To 
date, only a few examples of acrylated mucoadhesive materials have been reported, which have 
been obtained via a grafting to approach. The first example of an acrylated mucoadhesive 
polymer was poly(ethylene glycol) diacrylate (PEG-DA), reported by Davidovich-Pinhas and 
Bianco-Peled (Figure 11).[105]  
 
 
Figure 11. Examples of acrylated polymers; (a) PEG diacrylate, (b) Pluronic F127 diacrylate, 






The acrylation of PEG was achieved by reaction of the PEG terminal hydroxyl groups with 
acryloyl chloride under basic conditions. This same methodology was used to modify Pluronic 
F127, yielding thermoresponsive acrylated micelles which could subsequently as drug delivery 
devices for hydrophobic drugs.[106] In order it enhance the mucoadhesive capabilities of 
cationic PDMAEMA nanogels, Brannigan et al. quaternized the tertiary amine of the 
DMAEMA repeat units with acryloyl chloride, yielding highly mucoadhesive nanogels which 
were capable of encapsulating and releasing therapeutic compounds for the ocular drug 
delivery.[107] Most recently, Porfiryeva et al [108] used similar reaction for acrylation of Eudragit 
EPO, a terpolymer based on N,N-dimethylaminoethyl methacrylate with methylmethacrylate 
and butylmethacrylate. This material is manufactured by Evonik Industries AG and is approved 
as a pharmaceutical excipient. Acryloylation of   Eudragit EPO significantly improved its 
mucoadhesive properties, which was demonstrated fluorescent flow-through technique with 
sheep nasal mucosa. Using slug mucosal irritation assay it was demonstrated that acrylated 
Eudragit EPO is a non-irritant material, whose biocompatible properties are similar to the 
parent polymer.  
Acrylated chitosan was also synthesised by Shitrit et al [109] by reacting an excess of PEG-DA 
with free amine groups via a Michael-type reaction. These modified chitosan-based materials 
were found to have enhanced mucoadhesive properties when adhered to porcine intestinal 
tissues.  
Polymers modified with methacrylate groups also exhibit enhanced mucoadhesive properties 
similarly to acrylated materials. Kolawole et al [110] reported the synthesis of methacrylated 
chitosan with two degrees of substitution using its reaction with methacrylic anhydride. The 
retention of sodium fluorescein formulated with methacrylated chitosans was evaluated using 
flow-through technique with porcine bladder mucosa in vitro. It was established that 
methacrylated chitosan with greater degree of methacrylation (38.5 ± 3.9 %) exhibited superior 
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mucoadhesive performance compared to unmodified polysaccharide. The toxicological 
evaluation of methacrylated chitosans using UMUC3 cell viability studies indicated that 
methacrylation did not result in any unwanted reduction in material biocompatibility.   
 
Maleimide-functionalised materials 
One of the most recent advancements in the synthesis of mucoadhesive materials is the 
exploitation of the well-known maleimide-thiol ‘click-like’ reaction. Akin to thiomers and 
acrylated materials, maleimide-bearing materials covalently bind to the free thiols groups of 
cysteine residues present in mucin glycoproteins. First reported by the Khutoryanskiy group,93 
only a few examples are present in the literature to date of maleimide-bearing materials being 
used as mucoadhesive excipients. In the first instance, a protected maleimide acrylate monomer 
was synthesised and subsequently co-polymerised with N-vinyl pyrrolidone (NVP) via free-
radical emulsion polymerisation and deprotected to yield maleimide-bearing nanogels (Figure 
12(a)).[111] These nano-materials exhibited superior mucoadhesive capabilities than first 
generation mucoadhesives when applied to bovine conjunctive tissue. Furthermore, the 
nanogels were loaded with a model therapeutic agent and were found to be viable drug delivery 




Figure 12. Maleimide-bearing mucoadhesive materials; (a) copolymer of NVP and 
deprotected maleimide acrylate, (b) lipidyl PEG-maleimide, (c) PEG maleimide-grafted 
alginate and  (d) 6-maleimidohexanoic acid-grafted chitosan. 
In addition, Bianco-Peled et al, synthesised maleimide functional alginate by reacting excess 
commercially available PEG-bis-maleimide with a pre-synthesised thiolated alginate (Figure 
12 (b)).[112] It was found that the PEG maleimide-bearing alginate (Alg-PEGM) exhibited a 
two-fold increase in mucoadhesive properties when compared to the thiomer analogue. 
Furthermore, Alg-PEGM exhibited excellent bio-compatibility and were found to be non-toxic 
to normal dermal human fibroblast (NDHF) cells. Most recently, Kaldybekov et al. yielded 
maleimide-bearing liposomes utilising the commercially available maleimide-functional 
PEGylated lipid, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[maleimide(polyethylene glycol)-2000] ammonium salt (PEG2000-DSPE-Mal).[113] These 
liposomes were used as mucoadhesive chemotherapeutic delivery vehicles to the urinary 
bladder. It was found that the maleimide-bearing liposomes exhibited a superior in vitro 
retention on bladder mucosa, relative to non-functional liposomes, owing to the formation of 





reported the synthesis of 6-maleimidohexanoic acid-grafted chitosan (MHA-CHI) and its 
evaluation as a new mucoadhesive polymer in comparison with thiolated chitosan modified by 
conjugation with cysteine (Cys-CHI). Both derivatives of chitosan were formulated as tablets 
and their adhesion to porcine buccal membrane was studied using tensile test ex vivo. The 
mucoadhesive strength of tablets composed of MHA-CHI was significantly greater compared 
to Cys-CHI. Biocompatibility of MHA-CHI and CyS-CHI was also evaluated using MTT assay 
with normal human gingival fibroblast cells. It was established that both modified chitosans do 
not cause any toxicity reactions at polymer concentrations up to 1000 g/mL.  
 
N-hydroxy(sulfo)succinimide ester – functionalised materials 
A new class of polymers capable of binding to mucus components covalently was very recently 
introduced by Bernkop-Schnurch et al[115, 116]; these materials could specifically target amino 
groups of lysine and arginine present in mucin glycoproteins. These polymers were synthesised 
by covalently conjugating N-hydroxysuccinimide (NHS) or N-hydroxysulfosuccinimide 
(Sulfo-NHS) to PAA (Figure 13).  
 







Solid compacts were prepared based on these modified polymers and their adhesion to freshly 
excised porcine intestinal mucosa was evaluated using both rotating disc and tensile methods.  
The superior mucoadhesive properties of Sulfo-NHS-PAA were demonstrated compared to the 
parent polymer and it was related to the possibility of forming amide bond with mucins under 
physiological conditions.  Toxicological evaluation of Sulfo-NHS-PAA conjugates was 
conducted using hemolysis and Caco-2 cell assays. It was established that these materials did 
not show any haemolytic properties, except for 0.5 % solution of Sulfo-NHS-PAA containing 
885.5 mol/g sulfo-NHS-groups[116]. Sulfo-NHS-PAA conjugates also did not cause any 
toxicological effects on Caco-2 cells and exhibited better cytotoxicity profiles compared to 




Comparison of different strategies to enhance mucoadhesion  
Different strategies to enhance mucoadhesive properties of conventional polymers have been 
considered in this review. Table 2 presents the comparison of these strategies and highlights 
the mechanisms of enhanced mucoadhesion, progress in development of these materials as well 
as some advantages and disadvantages. So far, thiolated polymers are most widely researched 
as second generation mucoadhesives and there are already some examples of commercialised 
products. Other strategies to improve mucoadhesive performance of polymers have emerged 
only recently and have shown some advantages over polymeric thiomers. Further research will 
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be needed into these systems to establish if these could also be used in the future for developing 
new medicines for transmucosal drug delivery.  
Moreover, very little is currently known about the relative strength of adhesion for polymers 
prepared using different strategies. Further research is needed to establish some orders of 
adhesive strength for polymers modified with thiol, catechol, acrylate, methacrylate, 
maleimide, and N-hydroxy(sulfo)succinimide ester groups.  A comparison of other 
physicochemical and biological characteristics between these classes of materials will also be 
useful, including their storage stability and biocompatibility.  







Progress in research 







thiol groups in 
mucins 
>450 publications.  








Thiols are prone to 
oxidation, resulting in 












progress was made in 
the synthesis of these 
Catechols are prone to 
oxidation, which results in 
changes in material colour 

















progress was made in 
the synthesis of these 
materials for other 
medical 
applications[119] 
Possible limitations imposed 
by the conditions required 
for boronate-sugar 
interactions as the optimal 
pH needed is often above 
physiological ranges[89] No 






with thiol groups 
in mucins 
<5 publications.  
Potentially better storage 
stability compared to 
thiolated polymers. No 









Potentially better storage 
stability compared to 
thiolated polymers. No 











Adhesion to mucosal 
surfaces is not reliant on 
cysteine rich domains in 
mucins. No tendency for 




In conclusion, it is evident that the field of mucoadhesive materials has seen significant 
developments in recent times, predominantly as a consequence of advances in polymer 
chemistry and coupling techniques. From their inception mucoadhesive materials have 
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progressed from conventional water-soluble, natural and semi-synthetic polymers to multi-
faceted functional materials with higher architectures. Several classes of polymers with 
enhanced mucoadhesive performance have emerged in the recent decade in addition to already 
established thiolated materials. These include polymers bearing catechol-, boronate-, acrylate-
, methacrylate-, maleimide- and N-hydroxy(sulfo)succinimide ester- groups. We believe that 
the future of mucoadhesive materials lies in the discovery and exploitation of mucoadhesive 
functionalities in the synthesis of novel polymers. 
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